Completely agree, TAB, they certainly would mainta
Post# of 72440
Did you notice that they talked about optimizing dose? So it could be that it's working great on some people, not so much on others because the dosing is at VERY cautious levels -- like Kevetrin, in whose early stages had patients who were getting practically nothing. All you have to do is look at the news from a couple of weeks ago where the French researchers killed someone with too big a dose in Phase 1, to know that caution is by far the best plan with these drugs.